荟萃分析:炎症性肠病中衰弱的患病率及相关不良事件
该荟萃分析检索MEDLINE、EMBASE和EMBASE Classic数据库至2024年2月14日,纳入23项观察性研究共1,893,448名成人炎症性肠病患者,评估衰弱患病率及其与不良结局的关联。结果显示衰弱合并患病率为18%(95%CI 12.4%-25.6%),衰弱增加感染相关住院、术后并发症和死亡风险。
要点
- 炎症性肠病患者衰弱合并患病率为18%(95%CI 12.4%-25.6%)。
- 衰弱增加感染相关住院风险(RR 1.9;95%CI 1.2-3.0)。
- 衰弱增加术后并发症(RR 2.0;95%CI 1.4-2.7)和死亡风险(RR 4.3;95%CI 2.6-7.4)。
核心结论
- 衰弱在炎症性肠病患者中常见,并与感染相关住院、术后并发症和死亡等炎症性肠病相关不良结局相关。
- 未来工作应聚焦于开发风险评估工具,以更好地支持对患有衰弱的老年炎症性肠病患者的决策。
研究设计与样本
- 研究为荟萃分析,检索MEDLINE、EMBASE和EMBASE Classic数据库,检索时间从建库至2024年2月14日。
- 纳入标准为年龄≥16岁、确诊炎症性肠病且包含衰弱评估的成人研究。
- 共纳入23项观察性研究,涉及1,893,448名成人。
- 18项研究偏倚风险低,5项研究偏倚风险中等。
- 使用了12种衰弱评估方法,最常用的是医院衰弱风险评分(Hospital Frailty Risk Score)。
主要发现
- 炎症性肠病患者衰弱合并患病率为18%(95%CI 12.4%-25.6%)。
- 两项研究的未调整事件数据荟萃分析显示,衰弱增加治疗后感染相关住院风险(RR 1.9;95%CI 1.2-3.0)。
- 三项研究的未调整事件数据荟萃分析显示,衰弱增加术后并发症风险(RR 2.0;95%CI 1.4-2.7)。
- 七项研究的未调整事件数据荟萃分析显示,衰弱增加死亡风险(RR 4.3;95%CI 2.6-7.4)。
关键数值与推荐
- 衰弱合并患病率为18%(95%CI 12.4%-25.6%)。
- 衰弱与治疗后感染相关住院风险的RR为1.9(95%CI 1.2-3.0)。
- 衰弱与术后并发症风险的RR为2.0(95%CI 1.4-2.7)。
- 衰弱与死亡风险的RR为4.3(95%CI 2.6-7.4)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The number of adults aged over 60 years with inflammatory bowel disease (IBD) is increasing. Frailty, rather than chronological age, may be a better predictor of adverse health outcomes. AIMS: To summarise current knowledge about frailty in adults with IBD including the prevalence and associations of frailty and IBD-related adverse outcomes. METHODS: We performed an electronic search of MEDLINE, EMBASE and EMBASE Classic databases using search terms for IBD and frailty from inception to 14 February 2024. All studies involving adults aged ≥ 16 with a confirmed diagnosis of IBD that included a frailty assessment were eligible for inclusion. RESULTS: We included 23 observational studies involving 1,893,448 adults. Risk of bias was low for 18 studies and moderate for five. Twelve methods of frailty assessment were used, the most common being the Hospital Frailty Risk Score. Pooled prevalence of frailty in IBD patients was 18% (95% confidence interval (CI) 12.4%-25.6%). Meta-analysis of unadjusted events data demonstrated that frailty increased the risk of infection-related admissions following treatment in two studies (relative risk (RR) 1.9; 95% CI 1.2-3.0), post-operative morbidity in three (RR 2.0; 95% CI 1.4-2.7) and mortality in seven (RR 4.3; 95% CI 2.6-7.4). CONCLUSIONS: Frailty is common in patients with IBD and is associated with IBD-related adverse outcomes including infection-related admissions following treatment, post-operative morbidity and death. Future work should focus on developing risk assessment tools to better support decision making for older people with frailty and IBD.
引用
- Carbery I, Todd O, Hale M, et al. Meta-Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Diseases. Aliment Pharmacol Ther. 2024. PMID: 39524008. doi:10.1111/apt.18390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。